Diseases of the Endocrine System | Mental Health & Behavioral Research, Phase II-III

MitoQ for improving cognition in early course psychosis illnesses

Volunteers
Health Professionals

What is the purpose of this trial?

Cognitive impairments in schizophrenia-spectrum disorders can cause significant disability, and currently, there are no effective treatments for these cognitive challenges. This study aims to explores the potential of MitoQ, an antioxidant, to improve cognitive functions in individuals with early phase schizophrenia-spectrum disorders by reducing oxidative stress in mitochondria.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Nina Levine

nina.levine@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Vinod H. Srihari, MD
Professor of Psychiatry; Director, STEP Program; Fellow, Davenport College

Sub-Investigators

Last Updated
12/18/2025
Study HIC
#2000038056